A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects With Genotype 1, 4, 5 and 6 Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms LDV/SOF ESRD
- Sponsors Gilead Sciences
- 05 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 09 Mar 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.